A widely cited figure of six million state-registered medical marijuana patients is being misused as evidence of medical acceptance, according to sworn testimony filed in the DEA's marijuana-rescheduling hearing. The testimony argues that a registry card documents legal registration, not physician-supervised treatment or FDA-quality clinical evidence. This distinction matters for how policymakers, clinicians, and patients understand what the numbers actually represent.

What Does a Medical Marijuana Registry Card Actually Prove?

The core argument centers on a critical difference: a state registration is not the same as clinical evidence. When someone receives a medical marijuana card, they have completed a state's legal registration process. But that process does not necessarily mean they received individualized physician oversight, ongoing follow-up care, or outcomes tracked against a clinical standard. Duane Boise, President and CEO of MMJ International Holdings, a pharmaceutical developer with FDA Investigational New Drug filings for a cannabinoid drug candidate, stated in sworn testimony before Chief Administrative Law Judge Derek C. Julius that the distinction is fundamental to understanding the rescheduling debate.

"A registry card is not a clinical trial. A recommendation is not an FDA-approved prescription," Boise argued.

Duane Boise, President and CEO, MMJ International Holdings, Inc.

The testimony cites physician-participation data from several major state medical marijuana programs to support this point. According to the sworn statement, approximately 96% to 98% of physicians in these programs reportedly do not participate in issuing marijuana certifications at all. This means that the vast majority of licensed doctors in states with medical marijuana programs are not involved in the process, raising questions about whether six million registrations represent broad medical consensus or concentrated prescribing by a small number of high-volume providers.

How Concentrated Are Medical Marijuana Certifications Among Physicians?

The testimony also highlights uneven certification practices across states. In Colorado, for example, three physicians reportedly generated more than one-quarter of that state's marijuana recommendations. This concentration suggests that medical marijuana certifications are not distributed evenly across the physician community, but rather clustered among a small subset of practitioners. That pattern raises questions about whether the registry numbers reflect a broad consensus among the medical profession or a niche practice among a limited group of specialists.

The distinction between registry counts and clinical evidence has practical implications for how clinicians, policymakers, and patients should interpret the numbers in ongoing debates about cannabis regulation and rescheduling. Understanding what the six million figure does and does not represent is essential for making informed decisions about medical cannabis policy and patient access.

How Should Clinicians and Policymakers Use Registry Data?

• Registry Size Should Not Drive Referral Decisions: The number of state-registered patients should not be the primary factor in deciding whether to refer a patient for medical marijuana or recommend cannabis-based treatment. Individual patient assessment, clinical evidence for specific conditions, and physician-supervised follow-up remain the appropriate standards for clinical decision-making.
• Physician Participation Matters: When evaluating the credibility of medical marijuana programs, policymakers and clinicians should examine how many physicians in a state actually participate in certifications. Low participation rates suggest that the practice remains concentrated among specialists rather than integrated into mainstream medical care.
• Distinguish Legal Status from Clinical Evidence: A patient's legal registration status is separate from whether they have received evidence-based treatment. Clinicians should recognize that registry numbers reflect legal compliance, not necessarily clinical outcomes or physician-supervised care protocols.

It is important to note that this testimony comes from an interested party. MMJ International Holdings is a petitioner in federal litigation challenging the DEA's April 2026 rescheduling order and has significant financial stakes in how cannabis regulation evolves. The company holds two FDA Investigational New Drug filings and Orphan Drug Designation for a cannabinoid drug candidate in development for Huntington's disease. Readers should evaluate the testimony with awareness of this conflict of interest, while also recognizing that the underlying distinction between registry counts and clinical evidence is a legitimate question regardless of who raises it.

The DEA's marijuana-rescheduling hearing, which has been ongoing for the past two years, has drawn testimony from a wide range of interested parties, including state officials, patient advocates, industry groups, and pharmaceutical developers. This particular testimony contributes to an important conversation about how to interpret patient numbers and what they do and do not tell us about medical acceptance and clinical evidence in the cannabis field.

As the regulatory landscape for cannabis continues to evolve, clinicians and policymakers will need to maintain clear distinctions between patient access, legal registration, and clinical evidence. The six million figure may represent real patient demand and state-level policy decisions, but it does not automatically establish that six million patients received individualized physician oversight or that the medical profession broadly endorses cannabis as a first-line treatment for specific conditions. Understanding these nuances will be essential for responsible cannabis medicine practice and policy development going forward.